How much do rheumatologists and orthopaedists doctor’s modalities impact the cost of arthritis in Cyprus? by Andrioti, Despena et al.
Syddansk Universitet
How much do rheumatologists and orthopaedists doctor’s modalities impact the cost
of arthritis in Cyprus?
Andrioti, Despena; Kyprianou, Kypros ; Charalambous, George
Published in:
B M C Musculoskeletal Disorders
DOI:
http://www.biomedcentral.com/1471-2474/16/193
10.1186/s12891-015-0643-x
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Andrioti, D., Kyprianou, K., & Charalambous, G. (2015). How much do rheumatologists and orthopaedists
doctor’s modalities impact the cost of arthritis in Cyprus? B M C Musculoskeletal Disorders, 16(1), [193]. DOI:
http://www.biomedcentral.com/1471-2474/16/193, 10.1186/s12891-015-0643-x
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
RESEARCH ARTICLE Open Access
How much do rheumatologists and
orthopaedists doctors’ modalities impact
the cost of arthritis in Cyprus?
Despena Andrioti1*, Kypros Kyprianou2 and George Charalambous2
Abstract
Background: Osteoarthritis is one of the primary causes of long-term functional disability. With an estimated
13.5 % prevalence in the general population contributes to a significant financial burden both for patients and
healthcare systems. The purpose of this research is to highlight the direct annual cost of the disease to the private
healthcare sector of Nicosia.
Methods: A questionnaire based on Greek and international research was completed between 10/1/2012
and 11/30/2012, with a sample of 20 doctors specialists in orthopaedics and rheumatology (50 % of practising
physicians in the private sector). An assessment of the annual cost of medical procedures and tests, pharmacologic
therapies (modalities) and supplies per patient followed, based on current costs. Direct costs were assessed through
the micro-costing “bottom-up” approach. We isolated and separately priced the original diagnosis, followed by each
stage of the disease.
Results: The cost for the six predominant medical tests to establish a diagnosis and exclude mainly RA such as ESR,
CPR, and X-ray as well as a physician’s office visit was 150€ per patient. The average direct cost per patient during
stages 1, 2 and 3 of the disease was 280.54€, 1,834.64€ and 5,641.72€ annually, respectively, with an annual average
of 2,573€ per patient.
Conclusions: Even though during the period of the study, the country had not yet established clinical guidelines, the
participating physicians followed international practices. Significant rise in the cost in each stage of the disease
was found, with additional increases in the following years as a result of the expected increased prevalence of
the disease. It is noted here that uninsured patients, as well as those who qualified for free medical care, they
seek these services in the private sector, and had to pay out of pocket money for examination and treatment.
These patients, thus, contended with a serious financial burden. Therefore, it is important to inform them very
extensively regarding evidence-based management of the disease to aid them in coping with this chronic illness.
Background
Osteoarthritis is a chronic illness, which presents as a
result of degenerative joint disease primarily of the
upper and lower extremities. It mainly affects the elderly
population, but may in some cases affect younger gener-
ations. The main symptoms of osteoarthritis are joint
pain, which intensifies as a result of movement and
decreases when the patient is at rest [1, 2].
Osteoarthritis is a common disease and attributable to
50 % of musculoskeletal conditions. It is affecting 9.6 % of
men and 18 % of women over the age of 60 internation-
ally. It is notable that in 1990, it was estimated to be the
8th cause of disability internationally. With the increased
life expectancy and aging of the population osteoarthritis
will eventually be the 4th major cause of disability by the
year 2020 [3]. The knee is the main joint affected by osteo-
arthritis, followed by the hip. Osteoarthritis of these joints
affects approximately 10-12 % of the population over
65 years of age [4]. Under the age of 50, however, osteo-
arthritis is more prevalent in men, whereas, over the age
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of 50, it is more prevalent in women. This gender distinc-
tion continues and increases with age [5].
As research continues, it becomes more apparent that
the onset of the disease is not brought on by a single cause.
It appears that heredity plays a role in the development of
osteoarthritis. In addition, extrinsic factors contribute in its
development in persons with a genetic predisposition. The
major causes for the disease seem to be age, obesity, occu-
pational exposure (persons with occupational fatigue of the
knee or hip joints; standing, repeated bending of the knee
and hip joint and extensive walking), intensive practice in
athletics, such as football, high jump, weight lifting, etc.,
previous injuries and anatomical irregularities [6]. About
80 % of those with osteoarthritis experience low quality of
life as a result of feeling tenderness (pain) and restriction
of movement [7, 8], whereas 25 % cannot function nor-
mally in their daily lives [9, 10].
To establish a diagnosis, physicians utilize the patient’s
history and clinical examination. Therapy aims at alleviat-
ing the pain, preserving joint movement, as well as delay-
ing further deterioration of the joint cartilage [11]. In
order to achieve these objectives, pharmacological and
non-pharmacological therapies are used [12]. Pharmaco-
logical therapy is related to the level of deterioration of
the cartilage. Initially, a regiment of analgesics and anti-
inflammatory medications could be prescribed. However,
at later stages and in more serious cases, specialists may
prescribe a range of modalities that are not always recom-
mended for management of osteoarthritis by the profes-
sional bodies [13, 14] such as glucosamine or injections of
hyaluronic acid administered directly into the joint in
conjunction with strong opioids [15, 16]. Among the non-
pharmacological therapies a significant role play weight
loss, physical therapy, exercise, occupational therapy, pa-
tient education, as well as support from their social
networks [7, 17–20].
Even though current guidelines for the management of
osteoarthritis of the hip and knee include recommenda-
tions for effective financial interventions in terms of treat-
ment and disease management [18, 21, 22], osteoarthritis
is an expensive disease. As a result of its high prevalence,
it burdens both the health care systems and the patients
[23–25]. Studies showed that the cost of arthritis repre-
sents 1.5-2.4 % of the health budget or around 1.2 % of the
GDP in developed countries such as Australia, Canada,
France, UK and USA [26–29]. To determine direct cost,
pharmacological as well as non-pharmacological therapies
must be taken under consideration. Whereas to determine
indirect cost, other factors than those related to costs of
medication are equally important including absenteeism,
reduced productivity due to pain, sick benefits, informal
care cost, and premature mortality, depending on
which agent’s (employer, patient, insurance company,
society) perspective we examine. Inconsistencies in
methodology make it difficult to collect accurate cost
data, and thus comparisons in between countries and
healthcare systems are weak.
The research on the cost of osteoarthritis is very limited
in Cyprus. Therefore, our aim was to capture the direct
annual cost for each patient diagnosed with osteoarthritis
of the lower extremities, managed by a private orthopaed-
ist or rheumatologist at the Province of Nicosia, with
regards each one of the three stages of the disease. We
considered annual cost in the private sector more repre-
sentative, as it represents the market prices. It is totally
paid by the patient as out-of-pocket money.
Further, we wanted to highlight the prevalence of the
problem of osteoarthritis compared to other diseases
treated by these private practitioners as well as to show
the applied methods of management and treatment of
osteoarthritis by these physicians.
Cyprus with a population of about 800.000 lies in the
outermost borders of the European Union. In the country
two parallel health systems operate, a public and a private
one. The public system covers 85 % of the population
while the rest has to pay out of pocket money in order to
get health services. The out-of-pocket payments account
for about 40 % and it is one of the highest proportions of
household spending in Europe. The system is fragmented
and the coordination and communication within and
between public and private sectors is poor. It is very
common even patients who are entitled for free medical
care in the public sector to seek these services in the
private, mainly due to long waiting lists in the former [56].
Methods
Doctors’ population
Initially, the number of rheumatology and orthopaedic
specialists who were working in the private sector in the
Province of Nicosia was recorded, amounting to 40 physi-
cians (1:1000 residents). These physicians were personally
contacted. A detailed explanation was given as to the aim
of the study, as well as information on the potential bene-
fits they could gain from a possible participation in the
study, meaning that participation would enable them to
communicate their diagnostic and therapeutic modal-
ities for the treatment and management of patients with
chronic osteoarthritis. In addition, they would have the
opportunity to compare their diagnostic methodologies
to those of their colleagues. They were assured that pa-
tient confidentiality would be carefully safeguarded. The
study sample was 20 doctors, of whom 15 were orthopae-
dists and five rheumatologists, which was 50 % of these
private practice specialists of the Province of Nicosia.
The tool
The questionnaire (appendix) was built in accordance
with international bibliography [11, 14] and based on
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international guidelines. It included 25 questions relat-
ing to physicians’ profiles, the diagnostic and thera-
peutic methodologies they used during each stage of
osteoarthritis, and finally, any preventative and health
educational measures, which they recommended to
their patients for management of the disease. The comple-
tion of the questionnaire took place between 10/1/2012
and 11/30/2012.
Stages
The stages of the disease, as prescribed by clinical plus
radiographic criteria according to the American College
of Rheumatology [30–32], were as follows: Stage 1: mild
symptoms, Stage 2: strong symptoms, Stage 3: stronger
symptoms which may lead to immobility, Stage 4: severe
symptoms, which may lead to surgery and which are not
the subject of this study.
Ethics
There was no breach in patient privacy. We did not use
patients’ personal data. Therefore relevant consent was
not needed. The study protocol was submitted to and
approved by the national authorities i.e. the Cypriot
National Committee of Bioethics, the Cypriot Data
Protection Authority and the Ministry of Health. The
medical doctors who participated in the study completed
the questionnaire so that we considered that we have
their consent.
Estimation of direct cost
Our aim was to estimate the direct average annual cost
per patient in the different stages of the diseases. Patient
information was reported in a technical formal descriptive
systematic way. Some doctors utilized the relevant data at
their disposal while others used their experience to report
information. We applied the process of micro-costing,
which is known as "bottom-up approach" [33]. The initial
physician’s office visit/diagnosis was priced separately, as
well as the first three stages of osteoarthritis.
In order to estimate osteoarthritis patient’s direct an-
nual cost during each stage of the disease, we recorded
the fees for the medical tests required for the initial
diagnosis and for follow up with proper treatment for
each stage.
To evaluate direct annual costs, pharmacological and
non-pharmacological and adjunct modalities were re-
corded. Fees as listed on the webpage of the Ministry of
Health were used in order to price medical practices,
examinations, tests, medications and supplies. The Asso-
ciation of Physical Therapists provided the established
fees for physical therapy. Private diagnostic centers pro-
vided established fees for laboratory tests and X-Rays.
And finally, the Medical Association provided established
fees for physicians’ office visits and treatments. An Excel
table was used for each doctor to establish the descriptive
statistical analysis of the data and calculate the frequencies
of the variables. We collected for every doctor their
weekly, monthly and annual modalities per patient (phar-
maceuticals, supplies and laboratory tests) and added the
number of visits, for each one of the different stages of the
disease. We then calculated the average charge per patient
for these visits and modalities (pharmaceuticals, supplies
and laboratory tests) and adjusted it per patient per year.
Results and discussion
Among the physicians participating in the study, 92 %
were males. The majority, (35 %) were 60+ years old.
The number of patients with osteoarthritis amounted
to 8,550 (30 %) out of the total number of 28,500
patients that the participating physicians treated. Among
those, 3,420 (40 %) were males, whereas 5,130 (60 %)
were females. 6,412 (75 %) were Greek Cypriots, 1,282
(15 %) were citizens of other European Union member
countries, and 855 (10 %) were Turkish Cypriots. Regard-
ing medical insurance, 3,847 (45 %) were eligible for card
A, government health insurance (public servants are
eligible for this type of insurance as well as vulnerable
groups of the population with incomes less than 15,000€),
940 (11 %) had private health insurance, 769 (9 %) were
insured by various agencies, and the remaining patients
2,992 (35 %) were uninsured.
With reference to the various stages of the disease, the
participating physicians responded that they were treat-
ing 1,026 (12 %) patients who were in stage 1 of osteo-
arthritis, 3,078 (36 %) in stage 2, 3,762 (44 %) in stage 3.
The remaining patients were in the last stage of the dis-
ease, in other words the stage prior to surgery (Fig. 1).
During the first stage of the disease, the participating
physicians responded that their patients did not need
sick leave. During the second stage, 308 (10 %) patients
required 2–5 days of sick leave. During the third stage of
the disease, 2,257 (60 %) patients required 2–5 days sick
leave. Finally, during the fourth stage, 102 (15 %) re-
quired 7–10 days sick leave, whereas 581 (85 %) required
10 or more days of sick leave or even a certificate of
disability.
Fig. 1 Breakdown of patients enrolled in the sample of physicians
lists by stage of disease
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The last question (appendix) addressed new incoming
cases of osteoarthritis that the participating physicians
treated each year, which were close to 25 per physician.
Concerning patient referral to surgery within the past
year, the participating physicians responded that 30 of
their patients had surgeries of the hip and knee.
With reference to the comprehensive management of
the disease, all participating physicians (100 %) provided
preventive health care, counseling counselling on disease
self-management, weight loss, exercise and nutrition.
Cost of diagnosis
With an aim of diagnosing and placing the patient in the
respective stage of disease (primary, secondary, or tertiary
stage), all physicians prescribed X-rays of the affected joint
(100 %), whereas 85 %-95 % of the physicians responded
that they prescribed tests such as ESR, to classify patients
with RA or OA. Furthermore, C-Reactive Protein (CRP)
test was done to determine the level of inflammation. An
MRI was prescribed with a frequency of 45 %, whereas a
CAT scan was prescribed with a frequency of 65 %.
Finally, synovial fluid analysis was prescribed with a fre-
quency of 30 % and with a frequency of 20 % arthros-
copy was used to positively diagnose the disease and its
stages.
Based on these data, we estimated the average cost for
the diagnosis for three different scenaria of patients:
 First scenario: A patient would go through the most
common used tests, such as ESR, CRP and X-ray
used with a frequency of 85 % or more. The cost for
such tests is estimated at 120€ per patient. The total
diagnosis cost, including the physician’s office visit
was estimated at 150€ per patient.
 Second scenario: A patient would go through tests,
such as those used with a frequency of 45 % or more.
In this case, the aforementioned tests would be
administered, in addition to an MRI or CAT scan.
The total diagnosis cost, including the physician’s
office visit was estimated at 570€ per patient.
 Third scenario: A patient could go through all
possible tests, such as those used with a frequency
of 20 % or more. In this case, all the aforementioned
tests would be administered as well as a synovial
fluid analysis and/or an arthroscopy. The total cost
in this case, including the physician’s office visit was
estimated at 2,605€ per patient. Figure 2 demonstrates
the average estimated cost to establish a diagnosis.
Stage 1 cost of treatment
During stage 1 the average number of visits to the private
practitioner’s office was estimated at 1.4 per patient per
year. In addition, the total number of participating physi-
cians responded that they prescribe an X-ray annually.
The pharmacological treatment during stage 1 was
limited to simple analgesics and topical gels. The partici-
pating physicians prescribed paracetamol pain medica-
tions. Recommended dosage did not exceed one box per
month. The average per patient monthly cost for these
medications was 4.41€ monthly or 52.86€ annually.
In addition, they prescribed topical gels, such as muco-
polysaccharide, polysulphate and salicylic acid, diclofe-
nac and levomenthol. Recommended dosage did not
exceed one prescription per month with an average cost
of 6.02€ monthly or 72.18€ per patient annually.
Moreover, 65 % of doctors prescribed non-phar
macological (adjunct therapies), such as special shoes
(anatomic) with an average cost of 60€ per patient, and
(35 % of them) prescribed special stockings/socks with
an average cost of 45€, two pairs annually. Table 1 de-
picts the average cost per patient with 1st stage osteo-
arthritis annually, which exceeds 280.54€ annualy.
Stage 2 cost of treatment
During stage 2, the average physician’s office visits was
estimated at 1.7 per patient with an average cost of 51€.
An X-ray was prescribed annually, similar to stage 1.
The participating specialists prescribed paracetamol
and paracetamol/opioid pain medications at this stage.
Recommended dosage did not exceed one box per
month. The average cost was 5.84€ monthly or 70.03€
per patient annually. In addition, they prescribed the
same topical gels, such as mucopolysaccharide, polysul-
phate and salicylic acid, diclofenac and levomenthol.
Fig. 2 The average estimated cost to establish arthritis diagnosis in each of the three scenaria according to doctor’s modalities
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Recommended dosage was 1.55 per month with an
average cost of 11.88€ monthly or 220.97€ per patient
annually.
During stage 2, anti-inflammatory medications, such
as etoricoxib and diclofenac were prescribed with an
average of 1.25 boxes per month, at a cost of 18.48€
monthly or 221.73€ per patient annually. Furthermore,
gastroprofylaxis medicines were prescribed for all pa-
tients, such as pantoprazole and esomeprazole. Recom-
mended dose did not exceed one box per month, with
an average cost of these medications of 16.15€ monthly,
or 193.76€ per patient annually.
Moreover, 30 % of the sample were prescribed dietary
supplements, such as collagen with an average cost of
17.40€ monthly or 208.80€ per patient annually.
In addition, the participating physicians prescribed
2.15 physical therapy sessions with an average cost of
64.50€ monthly or 774.00 per patient annually.
The participating physicians (65 %) also prescribed
nonpharmacological therapies such as orthopedic shoe
inserts with an average cost of 250.00€ per patient,
special shoes (anatomic) with an average cost of 60€ per
patient, and (35 %) prescribed special stockings/socks
(two pairs annually) for osteoarthritis with a total cost of
90.00€ per patient. The total average cost of these means
was 132.76€ per patient annually. Table 2 depicts the
average cost per patient with stage 2 osteoarthritis which
exceeds 1,837.64€ per patient annually.
Stage 3 cost of treatment
During stage 3 the average physician’s office visits were
estimated at 5.35 per patient with an average annual cost
of 160.50€ per patient. It appears that 40 % of the partici-
pating physicians prescribed an annual synovial fluid ana-
lysis with an average cost of 14€, an annual X-ray and an
MRI (55 %) with an average cost of 205€ per patient.
The participating physicians prescribed parecetamol/
opioid pain medications similar to stage 2. Recommended
dosage did not exceed two boxes per month. The average
cost was 12.38€ monthly or 148.50€ per patient annually.
In addition, the same topical gels were prescribed as in
stage 2. The average use of topical gels was reduced in
comparison to the second stage and amounted to 220.97€
per patient annually.
The same anti-inflammatory medications were used
during this stage as in stage 2 of the disease with an
average prescription of 1.45 box per month, with an
average cost of 33.93€ monthly or 407.15€ per patient
annually.
Furthermore, gastroprofylaxis medicines were pre-
scribed as in stage 2 of the disease. Recommended dose
did not exceed two boxes per month. The average cost
of these medications was 46.87€ monthly or 562.41€
per patient annually.
In addition, an injection of hyaluronic acid was recom-
mended by 70 % of the participating physicians, to be
administered annually. The average cost for this treat-
ment was 280.00€ per patient. 60 % of the participating
physicians also recommended annual corticosteroid in-
jections. The average cost for this treatment was 42.00€
per patient annually.
Moreover, 40 % of the participating physicians pre-
scribed dietary supplements, such as collagen with an
average cost of 23.20€ monthly or 278.40€ per patient
annually.
Physical therapy was prescribed on an average 8.65
times per month, with an average cost of 259.50€ monthly
or 3,114.00€ per patient annually.
The participating physicians considered certain sup-
portive means for assistance necessary at this stage. As a
result, canes and special stockings for osteoarthritis were
recommended at a cost of 40€ and 80€ per patient
respectively. About 60 % of the participating physicians
recommended orthopaedic shoe inserts with an average
cost of 250.00€ per patient, whereas special shoes (ana-
tomic) with an average cost of 60€ per patient were
recommended by 40 % of the sample. The total average
cost of these means was 304€ per patient annually.
Table 3 depicts treatment cost during stage 3 of the
disease, which exceeds 5,641.72€ per patient annually.
Table 1 Annual average cost per patient with stage 1
osteoarthritis
Type Cost €
Visit 42.00
X-Ray 40.00
Pain medications 52.86
Gels 72.18
Shoes and socks 73.50
Total 280.54
Table 2 Annual average cost per patient with stage 2
osteoarthritis
Type Cost €
Visit 51.00
X-Ray 40.00
Pain medications 70.03
Anti-inflammatory 221.73
gels 142.56
Gastro prophylaxis medicines 193.76
Dietary supplements (collagen) 208.80
Physiotherapies 774.00
Adjunct means (shoes, socks, insoles) 132.76
Total 1,837.64
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In Fig. 3, the average cost per patient annually appears.
Discussion
Osteoarthritis is a chronic illness that affects mainly
middle-aged and older adults, causing mobility problems
and diminishing their quality of life [34]. As a result of
the generally increased life expectancy, patients with
chronic osteoarthritis are also expected to live longer,
but with their deteriorating health, they are subjected to
a constant increase in treatment costs posing a substan-
tial burden to national health systems, insurance funds
and family budgets [6, 35–37].
Based on outcomes from the present study, it appears
that osteoarthritis is a very serious healthcare issue in
the country, since 30 % of patients over 40 who visit the
20 participating specialists suffer from osteoarthritis. In
addition, in Cyprus there is a free access to medical spe-
cialists, in other words, there is no gate keeping system.
As a result, the patients visit orthopedists and rheuma-
tologist as a first choice practitioner for diagnosis and
treatment and mostly in the private sector [38, 39]. More
specifically, similar findings from other studies showed
that women, well-educated individuals and people with
worse health status are more likely to visit private prac-
tice providers.
As expected, osteoarthritis affects females (60 %) more
than males. The fact that most patients who visited the
doctor were in stages 2 or 3 of the disease, points not only
to the importance of preventive care, but also indicates a
need of empowering patients to manage their illness. It
appears then that patients in stage 1 of the disease as a
result of mild symptoms do not have substantial difficulty
in their daily lives. In addition, as expected, patients in
stages 2 and 3 of the disease require more sick days.
Regarding to the development of the disease, the private
orthopedists and rheumatologists in Nicosia treat an aver-
age of 25 new patients each annually.
All participating physicians made recommendations for
better disease management, exercise, weight loss, physical
therapy and following a better nutrition regiment.
Alternative therapies for osteoarthritis, as suggested
by the current bibliography [40], such as acupuncture,
Tai Chi, Oigong and Yoga are not commonly used, nor
recommended by the participating physicians in our
country.
The study also showed that participating physicians
followed scientific developments in their specialties and
were well informed about diagnostic [15] and therapeutic
recommendations [41] as appears from their manage-
ment, which was similar with very few exceptions. Private
practice specialists should take into consideration the cost
of recommended modalities together with their efficiency,
Table 3 Annual average cost per patient with stage 3
osteoarthritis
Type Cost €
Visit 160.50
Synovial fluid analysis 14.00
X-Ray MRI 205.00
Pain medications 148.5
Anti-inflammatory 407.15
Gels 125.76
Gastro prophylaxis medicines 562.41
Dietary supplements (collagen) 278.40
Corticosteroid injections 42.00
Hyaluronic acid 280.00
Physiotherapies 3.114.00
Adjunct means (shoes, socks, insoles) 304.00
Total 5,641.72
Fig. 3 Patient’s average annual cost of osteoarthritis during each of the three stage
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and this is very important in light of the current financial
situation in the country.
As shown by this study specialists in Cyprus offer
more services to osteoarthritis patients [42–45]. Labora-
tory tests prescribed for the diagnosis and placement of
the patients in the correct stage of the disease as de-
scribed by the private practitioner such as ESR, CRP and
RA together with X-ray were primarily six, which in
conjunct with the cost of the physician’s office visit were
estimated at 150€ per patient. If an MRI or CAT scan
were additionally prescribed the cost exceeded 570€ per
patient. Finally, if patients were subjected to a synovial
fluid analysis and/or arthroscopy, the cost for diagnostics
would exceed on the average 2,600€ per patient.
The cost to patients in stage 1 of osteoarthritis exceeded
on average 280.54€ annually and included analgesic medi-
cations, such as paracetamol pain medications and topical
gels, such as mucopolysaccharide, polysulphate and sali-
cylic acid, diclofenac and levomenthol.
During stage 2 of the disease, the cost for analgesic
medications (paracetamol /opioid) and topical gels in-
creased, because they were ingested more frequently. In
addition, according to the majority of the participating
physicians, during stage 2, patients were prescribed anti-
inflammatory medications in conjunction with PPI’s for
gastroprophlaxis that were from the other medications
prescribed, as well as nutrition supplements. The most
important increase in cost, however, was brought on by
the use of nonpharmacological treatments, as well as
physical therapy, which contribute in increasing the
average direct cost to 1,834.64€ per patient annually.
Compared to the prior stages of the disease, the cost
climbed exponentially during stage 3. The patients had to
visit the physician’s office more often and many needed as-
sistance via artificial means to walk. In addition, during
stage 3, physical therapy and medications were prescribed
more frequently consequent to pain increase. The exten-
sive deterioration of the joint led participating physicians
to use corticosteroid or hyaluronic acid injections annually,
which aided in strengthening the elasticity of the joint. In
addition, during this stage, patients were subjected to add-
itional tests so that their physicians had a clearer picture of
the patients’ need for surgical intervention. As a result, the
patient with stage 3 osteoarthritis dealt with additional
costs from the added synovial fluid analysis and MRI. The
average direct cost exceeded 5,600€ per patient annually.
Overall, the cost for the disease has increased during
the last decades. On the average, one third of the direct
expenditures for osteoarthritis goes to pharmacologic
therapies, many of which are used to alleviate the pain
caused by the illness [46, 47].
Our research showed that the average annual direct cost
of osteoarthritis in Cyprus is substantial, and that it esca-
lates as the disease progresses. It ranges between 280.54€
for stage 1 patient annually, 1,834.64€ for stage 2 patient
annually, and 5,641.72€ for stage 3 patient annually,
resulting in an average direct cost of 2,573€ per patient
annually. Similar international research showed an average
total cost per patient ranging from 1,326€ in Italy [48–50]
to 4,564€ in USA [26], while the direct cost varies from
403€ for France [51] to 4,040€ for Canada [52, 53].
It is difficult to draw concrete conclusions in terms of
the factors that affect cost in every country. These varia-
tions may be due to different methods of cost calculations
and highlight the importance of the harmonization of rele-
vant cost measurement methods.
However, aggregated data at the national level high-
light the importance of the issue and the economic
burden of OA on the national health budgets of devel-
oped countries. More specifically, in 2001 in Australia,
it was noted that over 7.3 % of the general population
suffered from osteoarthritis and that the average cost of
treatment exceeded 2.4 % of the total healthcare expen-
ditures [54]. A similar study conducted in the USA in
2003 discovered that 27 million persons suffered from
osteoarthritis, in other words 12.1 % of the general popu-
lation, and that the average cost of treatment reached
1.2 % of the GDP [27–29]. In France, more than 13
million persons were examined to determine whether they
had the disease at a cost of 1.7 % of the total expenditure
of their healthcare system in 2002 [55] while in Spain, this
exceeded 4.7 million euro [49].
The cost for the management of osteoarthritis depends
on the number and range of services and the cost of
treatment (medical, pharmacological, diagnostic and
adjunct). The price of these treatments differs from
country to country, and depends largely on labor fees as
well as healthcare policies and cost of healthcare services,
based on the supply and demand that are applicable to
each country. In addition, different methodologies and
lack of standardization in processing cost make compari-
sons between countries difficult.
Healthcare services for OA in Cyprus appear to be
slightly higher than in other countries but in the same
magnitude. It may be attributed to a larger number of pre-
scribed laboratory tests, non-pharmacological support,
and physical therapy. Regarding the increase in cost the
method of payment (fee for service) could be blamed,
which encourages the increase in the number of services
rendered and contributes to the increase in cost, as well as
lack of national guidelines implementation, coupled with
patient demand for more services (adjunct means, diag-
nostic tests and medications), which contribute in the pri-
vate practitioners’ compliance with such demands so that
they do not lose their patients (customers).
Even though half of these patients qualified for free
medical care in the public sector, they, nonetheless, pre-
ferred to seek medical treatment in the private sector. This
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demand of private practice healthcare services in Cyprus
can be found in other studies as well. It would be interest-
ing to see how the economic crisis influenced the patient’s
behavior.
Conclusions
The prescription patterns of medical specialists contribute
to higher consumption and cost of services both for the
patients and the health system. In line of a further increase
of OA cost, that is expected, as a result of the rapid
increase of two major determinants, aging and obesity, the
central government should re-examine policies toward
patients with chronic illnesses, creating a national policy
for osteoarthritis. Doctor’s should be encouraged to use
guidelines with an aim at improving quality, efficiency and
cost containment. Emphasizing on the implementation of
clinical guidelines by medical doctors and empowering
patients regarding disease management and rational use of
health services are major elements they should invest in
the coming years. The current financial crisis in the coun-
try can help the reorganization of health services in terms
of cost effectiveness in cooperation with all stakeholders.
Limitation of the study
This study is only limited to the direct annual cost per
patient. For a comprehensive analysis of the burden of OA
indirect cost should be included as well. Furthermore, for
an overview of the financial burden of disease it would be
interesting to see the lifetime average cost of the disease.
The study refers to the private sector orthopaedic and
rheumatologist physicians’ modalities in the region of
Nicosia. Even though the sample was small (50 % of
practicing physicians), one may expect to a certain
extent similar results in the rest of the four regions as
well as in those countries where the relation doctor/
patient is characterised by the same values and beliefs
as pointed out above. Furthermore, due to the fact that
we did not use patients’ personal data, we did not
match patients and doctors. Cultural reasons may lead
the same patients visit more doctors for diagnosis and
treatment and thus bias the number of patients with
OA in the country.
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